

## HEAD AND NECK DISEASE SITE COMMITTEE

VIRTUAL SPRING MEETING  
SUNDAY MAY 1ST, 2022, 10:00 AM – 02:00 PM

CHAIR: JOHN WALDRON  
SENIOR INVESTIGATOR: WENDY PARULEKAR

### CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

### Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group or its collaborators.
- To provide a learning environment supportive to new investigators.

10:00 am	<b><u>Welcome</u></b>	<b>John Waldron</b>
	<b><u>New Concepts/Proposals</u></b>	
10:10 am	Immune Score Prognostic Marker Initiated Radiation de-Escalation ( <b>INSPIRE</b> ) for HPV-positive OPSCC ( <b>INSPIRE</b> )	<b>Anthony Nichols and David Palma</b>
	<b><u>Update on Approved Ongoing Proposals</u></b>	
10:25 am	<b>HN.13</b> - Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment ( <b>ON-TASC Study</b> )	<b>Ian Poon</b>
10:40 am	<b>HN.12</b> - <b>Promote-HN-</b> PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma	<b>Anna Spreafico</b>
10:55 am	<b>HN.11-</b> SPECT-CT Guided <b>ELE</b> ctive <b>C</b> ontralateral Neck <b>T</b> reatment in Lateralized Oropharynx Cancer ( <b>SELECT</b> ): For Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial	<b>John DeAlmeida and Ali Hosni</b>
11:10 am	<b>HN.10-</b> A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy ( <b>EVADER</b> ) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma	<b>Scott Bratman</b>

<b>11:25 am</b>	<b>HN.9-</b> Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)	<b>Khalil Sultanem</b>
<b>11:40 am</b>	<b>HNC.2</b> (NRG-HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	<b>Eric Winqvist</b>
<b>11:55 pm</b>	<b><u>Canadian Cancer Society Grant Update</u></b>	<b>Wendy Parulekar</b>
<b>12:10 pm</b>	<b><u>Other Business</u></b>	
<b>12:30</b>	<b><u>Lunch Break</u></b>	
	<b><u>Guest Speaker</u></b>	
<b>1:00 pm</b>	Directions for the Head and Neck Cancer Portfolio at NRG Oncology	<b>Sue Yom</b>
<b>2:00 pm</b>	<b><u>Meeting Adjourned</u></b>	